|
| 원발성 사구체신염에서 염산 Dilazep ( Cormelian ) 의 뇨단백 및 신기능에 대한효과에 관한 연구 |
| 박찬신 , 김기용 , 강덕희 , 강신욱 , 김흥수 , 하성규 , 한대석 , 이호영 |
|
|
| Abstract |
|
A clinical trial of antiplatelet agent (dilazep) was performed in patients with primary glomerulonephritis. Forty-four patients were treated with dilaxep 300 mg per day for 160±51 days. The pre-treatment baseline creatinine clearance was 72.4±41.8 ml per minute per l. 73 m of body-surface area and the mean 24 hour urine protein was 3366±3567 mg per day. The amount of proteinuria was increased to 4823±5226 mg per day after 4 months (p<0.05). The creatinine clearance was decreased to 56.3±32.1 ml per minute per 1.73 m of body surface area but there was no statistical significance. Among 44 patients only 8 were responded to the treatment with 20% decrease in proteinuria after 3 months. The response group had relatively low levels of BUN and serum creatinine as compared with the none-response group. And there was no significant side effect of the drug. |
|
PDF Links
Download Citation
